Be Biopharma

Engineered B Cells

Undisclosed RD rare diseases

Be BioPharma is developing Engineered B Cell Medicines (BeCMs). In response to disease, a single B cell produces proteins at rates of thousands per second to maintain health. Be Biopharma has built a three-step platform to modify the B cells to produce therapeutic proteins needed for a specific disease: engineer B cells, expand to secreting plasma cells, and infuse into patients. The modularity of the platform enables them to develop BeCMs for a broad range of diseases. The main goal is to create a new class of highly durable, off-the-shelf, redosable medicines that provide long-lasting production of therapeutic proteins. These will be tested against rare diseases and oncology initially and are in progress towards the clinic.